Praxis Precision Medicines Management
Management criteria checks 4/4
Praxis Precision Medicines' CEO is Marcio De'Souza, appointed in Apr 2020, has a tenure of 6.42 years. total yearly compensation is $8.71M, comprised of 7.6% salary and 92.4% bonuses, including company stock and options. directly owns 0.003% of the company’s shares, worth $217.85K. The average tenure of the management team and the board of directors is 5.3 years and 4.9 years respectively.
Key information
Marcio De'Souza
Chief executive officer
US$8.7m
Total compensation
| CEO salary percentage | 7.57% |
| CEO tenure | 6.4yrs |
| CEO ownership | 0.003% |
| Management average tenure | 5.3yrs |
| Board average tenure | 4.9yrs |
Recent management updates
Recent updates
Praxis Precision Medicines: Still Potential Upside After Huge Rally (Rating Upgrade)
Summary Praxis Precision Medicines has surged over 1,000% since April 2025, driven by pivotal clinical wins for ulixacaltamide and relutrigine. Ulixacaltamide and relutrigine, both with 2026–2027 PDUFA dates, target large, underserved CNS markets with combined peak sales potential exceeding $15 billion. PRAX's $1.4 billion cash position supports a commercial buildout and reduces near-term capital market risk, with further upside from potential out-licensing and priority review vouchers. Despite the meteoric share run, PRAX retains significant upside, justifying a small investment, with covered calls offering an attractive entry strategy. Read the full article on Seeking Alpha
PRAX: Vormatrigine Trial Setbacks Will Drive Future Repricing Risk
Analysts have lifted the fair value estimate for Praxis Precision Medicines to $188 from $162, reflecting higher modeled revenue potential for its late stage epilepsy and essential tremor programs, partially offset by a higher discount rate, slightly lower profit margin assumptions, and a richer future P/E multiple. Analyst Commentary Recent Street research on Praxis Precision Medicines shows a wide spread in price targets and views, with several firms highlighting both upside scenarios around epilepsy and essential tremor assets and execution risks tied to clinical outcomes and commercialization.
PRAX: Essential Tremor Launch Prospects Will Drive Future Upside Despite Seizure Trial Uncertainty
Praxis Precision Medicines enters this Narrative Update with the analyst price target higher in absolute dollar terms, supported by research that reflects revised fair value estimates, updated discount rates, refreshed revenue and margin assumptions, and a lower future P/E multiple in response to recent trial outcomes and pipeline commentary. Analyst Commentary Recent research on Praxis Precision Medicines presents a mixed picture, with several firms adjusting price targets and updating models after clinical readouts and management commentary.
PRAX: Late Stage Neurology Pipeline Will Drive Future Upside Potential
The analyst price target for Praxis Precision Medicines moved from $843 to $1,201, with analysts pointing to potential approvals for ulixacaltamide and relutrigine, along with ongoing interest in the broader late stage pipeline as key reasons for their updated assumptions. Analyst Commentary Recent Street research on Praxis Precision Medicines reflects a wide range of views, but several bullish analysts highlight what they see as meaningful upside tied to the company’s late stage neurology pipeline.PRAX: Vormatrigine Trial Setbacks Will Drive Future Repricing Risk
Analysts now place a $162.00 price target on Praxis Precision Medicines, adjusted from an earlier fair value estimate of about $85.76. This reflects updated views on discount rate, revenue growth potential, profit margins, and future P/E assumptions following recent trial outcomes and broader Street research.PRAX: Ulixacaltamide Tremor Opportunity Will Drive Future Upside Despite Vormatrigine Setback
Analysts have lifted their blended price target on Praxis Precision Medicines to about $618 from roughly $449, reflecting updated assumptions for ulixacaltamide's multi billion dollar sales potential in essential tremor and a lower, but still present, probability of success for vormatrigine after the POWER1 miss and POWER2 pause. Analyst Commentary Street research on Praxis Precision Medicines is split between enthusiasm for the ulixacaltamide opportunity and caution around execution risk after the POWER1 outcome for vormatrigine.Praxis: A High-Risk, High-Reward Epilepsy Play Post Ulixacaltamide (Rating Upgrade)
Summary Ulixacaltamide’s Phase 3 study was recommended to stop for futility, significantly lowering its chances of success in essential tremor. Investor focus shifts to the epilepsy pipeline, led by vormatrigine (focal epilepsy) and relutrigine (SCN2A/SCN8A-DEEs). Vormatrigine must differentiate from Xcopri and XEN1101 in a highly competitive focal epilepsy market. Relutrigine showed promising seizure reduction in rare pediatric epilepsies but needs confirmation in larger pivotal trials. Praxis has $400M+ cash, funding operations into 2028, with key epilepsy trial readouts expected in 2H 2025. Read the full article on Seeking AlphaPraxis Precision Medicines: Multiple Potential Drivers
Summary Praxis Precision Medicines, Inc., a promising clinical stage biopharma concern, has seen significant stock gains in the second half of 2024. Analyst firms are quite bullish on the stock, with eight firms recently issuing Buy ratings and price targets ranging from $114 to $305 per share. The company has several potential drivers with its late-stage pipeline candidates and possesses a decent balance sheet. While the stock should only be considered by aggressive investors given its recent rally, I have taken a small position in PRAX stock via covered call orders. An analysis around Praxis Precision Medicines follows in the paragraphs below. Read the full article on Seeking AlphaPraxis Precision Medicines: Great Price Movement, But Still Not Convinced
Summary Praxis Precision Medicines has shown impressive growth, but past trial failures and current risks warrant caution before investing. The lead candidate, Ulixacaltamide, is in a phase 3 trial for essential tremor, with results expected by the end of 2024. PRAX-628 shows promise for epilepsy, but the small patient cohort and competitive landscape raise concerns. Despite significant stock gains, I remain unconvinced and seek more data before making an investment decision. Read the full article on Seeking AlphaCEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$339m |
| Mar 31 2026 | n/a | n/a | -US$327m |
| Dec 31 2025 | US$9m | US$659k | -US$303m |
| Sep 30 2025 | n/a | n/a | -US$273m |
| Jun 30 2025 | n/a | n/a | -US$251m |
| Mar 31 2025 | n/a | n/a | -US$213m |
| Dec 31 2024 | US$13m | US$640k | -US$183m |
| Sep 30 2024 | n/a | n/a | -US$151m |
| Jun 30 2024 | n/a | n/a | -US$124m |
| Mar 31 2024 | n/a | n/a | -US$125m |
| Dec 31 2023 | US$2m | US$625k | -US$123m |
| Sep 30 2023 | n/a | n/a | -US$138m |
| Jun 30 2023 | n/a | n/a | -US$157m |
| Mar 31 2023 | n/a | n/a | -US$183m |
| Dec 31 2022 | US$6m | US$625k | -US$214m |
| Sep 30 2022 | n/a | n/a | -US$231m |
| Jun 30 2022 | n/a | n/a | -US$232m |
| Mar 31 2022 | n/a | n/a | -US$208m |
| Dec 31 2021 | US$11m | US$571k | -US$167m |
| Sep 30 2021 | n/a | n/a | -US$135m |
| Jun 30 2021 | n/a | n/a | -US$111m |
| Mar 31 2021 | n/a | n/a | -US$88m |
| Dec 31 2020 | US$12m | US$385k | -US$70m |
Compensation vs Market: Marcio's total compensation ($USD8.71M) is about average for companies of similar size in the US market ($USD8.47M).
Compensation vs Earnings: Marcio's compensation has been consistent with company performance over the past year.
CEO
Marcio De'Souza (47 yo)
Mr. Marcio Silva De'Souza M.B.A., has been President, Chief Executive Officer and Director of Praxis Precision Medicines, Inc. since April 2020. Mr. De'Souza joined the Praxis Precision Medicines, Inc. in...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.4yrs | US$8.71m | 0.0026% $ 217.8k | |
| CFO & Treasurer | 5.3yrs | US$3.20m | 0.033% $ 2.7m | |
| General Counsel & Secretary | 6.3yrs | US$2.84m | 0.024% $ 2.0m | |
| Co-Founder and President of Research & Development | no data | no data | no data | |
| Chief Operating Officer | less than a year | no data | 0.024% $ 2.0m | |
| Chief Technical Operations Officer | 4.8yrs | no data | no data | |
| Chief People Officer | 5.8yrs | no data | 0.013% $ 1.1m | |
| Chief Regulatory & Quality Officer | 6yrs | no data | no data | |
| Chief of Staff | 4.5yrs | no data | no data | |
| Head of Clinical Strategy | less than a year | no data | no data |
Experienced Management: PRAX's management team is seasoned and experienced (5.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.4yrs | US$8.71m | 0.0026% $ 217.8k | |
| Independent Director | 9.8yrs | US$418.72k | 0.0068% $ 567.6k | |
| Independent Chairman of the Board | 6yrs | US$445.22k | 0.062% $ 5.2m | |
| Independent Director | 7.5yrs | US$426.22k | 0.00067% $ 55.9k | |
| Independent Director | 5.4yrs | US$416.72k | 0% $ 0 | |
| Independent Director | 4.3yrs | US$421.22k | 0.0084% $ 698.6k | |
| Independent Director | 5.4yrs | US$412.72k | 0% $ 0 | |
| Member of Scientific Advisory Board | 3.7yrs | no data | no data | |
| Chairman of the Scientific Advisory Board | 3.7yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.7yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.7yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.7yrs | no data | no data |
Experienced Board: PRAX's board of directors are considered experienced (4.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/21 07:31 |
| End of Day Share Price | 2026/09/18 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Praxis Precision Medicines, Inc. is covered by 29 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Joel Beatty | Baird |
| null null | Baird |